Researcher tending seedlings in a laboratory environment. PHOTO: FREEPIK
Bindwell is testing a simple idea: use AI to design smarter, more targeted pesticides built for today’s farming challenges.
Updated
November 14, 2025 10:48 PM
Researcher tending seedlings in a laboratory environment. PHOTO: FREEPIK
Bindwell, a San Francisco–based ag-tech startup using AI to design new pesticide molecules, has raised US$6 million in seed funding, co-led by General Catalyst and A Capital, with participation from SV Angel and Y Combinator founder Paul Graham. The round will help the company expand its lab in San Carlos, hire more technical talent and advance its first pesticide candidates toward validation.
Even as pesticide use has doubled over the last 30 years, farmers still lose up to 40% of global crops to pests and disease. The core issue is resistance: pests are adapting faster than the industry can update its tools. As a result, farmers often rely on larger amounts of the same outdated chemicals, even as they deliver diminishing returns.
Meanwhile, innovation in the agrochemical sector has slowed, leaving the industry struggling to keep up with rapidly evolving pests. This is the gap Bindwell is targeting. Instead of updating old chemicals, the company uses AI to find completely new compounds designed for today’s pests and farming conditions.
This vision is made even more striking by the people leading it. Bindwell was founded by 18-year-old Tyler Rose and 19-year-old Navvye Anand, who met at the Wolfram Summer Research Program in 2023. Both had deep ties to agriculture — Rose in China and Anand in India — witnessing up close how pest outbreaks and chemical dependence burdened farmers.
Filling the gap in today’s pesticide pipeline, Bindwell created an AI system that can design and evaluate new molecules long before they hit the lab. It starts with Foldwell, the company’s protein-structure model, which helps map the shapes of pest proteins so scientists know where a molecule should bind. Then comes PLAPT, which can scan through every known synthesized compound in just a few hours to see which ones might actually work. For biopesticides, they use APPT, a model tuned to spot protein-to-protein interactions and shown to outperform existing tools on industry benchmarks.
Bindwell isn’t selling AI tools. Instead, the company develops the molecules itself and licenses them to major agrochemical players. Owning the full discovery process lets the team bake in safety, selectivity and environmental considerations from day one. It also allows Bindwell to plug directly into the pipelines that produce commercial pesticides — just with a fundamentally different engine powering the science.
At present, the team is now testing its first AI-generated candidates in its San Carlos lab and is in early talks with established pesticide manufacturers about potential licensing deals. For Rose and Anand, the long-term vision is simple: create pest control that works without repeating the mistakes of the last half-century. As they put it, the goal is not to escalate chemical use but to design molecules that are more precise, less harmful and resilient against resistance from the start.
Keep Reading
Examining the shift from fast answers to verified intelligence in enterprise AI.
Updated
November 7, 2025 9:31 PM
Startup employee reviewing business metrics on an AI-powered dashboard. PHOTO: FREEPIK
Neuron7.ai, a company that builds AI systems to help service teams resolve technical issues faster, has launched Neuro. It is a new kind of AI agent built for environments where accuracy matters more than speed. From manufacturing floors to hospital equipment rooms, Neuro is designed for situations where a wrong answer can halt operations.
What sets Neuro apart is its focus on reliability. Instead of relying solely on large language models that often produce confident but inaccurate responses, Neuro combines deterministic AI — which draws on verified, trusted data — with autonomous reasoning for more complex cases. This hybrid design helps the system provide context-aware resolutions without inventing answers or “hallucinating”, a common issue that has made many enterprises cautious about adopting agentic AI.
“Enterprise adoption of agentic AI has stalled despite massive vendor investment. Gartner predicts 40% of projects will be canceled by 2027 due to reliability concerns”, said Niken Patel, CEO and Co-Founder of Neuron7. “The root cause is hallucinations. In service operations, outcomes are binary. An issue is either resolved or it is not. Probabilistic AI that is right only 70% of the time fails 30% of your customers and that failure rate is unacceptable for mission-critical service”.
That concern shaped how Neuro was built. “We use deterministic guided fixes for known issues. No guessing, no hallucinations — and reserve autonomous AI reasoning for complex scenarios. What sets Neuro apart is knowing which mode to use. While competitors race to make agents more autonomous, we're focused on making service resolution more accurate and trusted”, Patel explained.
At the heart of Neuro is the Smart Resolution Hub, Neuron7’s central intelligence layer that consolidates service data, knowledge bases and troubleshooting workflows into one conversational experience. This means a technician can describe a problem — say, a diagnostic error in an MRI scanner — and Neuro can instantly generate a verified, step-by-step solution. If the problem hasn’t been encountered before, it can autonomously scan through thousands of internal and external data points to identify the most likely fix, all while maintaining traceability and compliance.
Neuro’s architecture also makes it practical for real-world use. It integrates seamlessly with enterprise systems such as Salesforce, Microsoft, ServiceNow and SAP, allowing companies to embed it within their existing support operations. Early users of Neuron7’s platform have reported measurable improvements — faster resolutions, higher customer satisfaction and reduced downtime — thanks to guided intelligence that scales expert-level problem solving across teams.
The timing of Neuro’s debut feels deliberate. As organizations look to move past the hype of generative AI, trust and accountability have become the new benchmarks. AI systems that can explain their reasoning and stay within verifiable boundaries are emerging as the next phase of enterprise adoption.
“The market has figured out how to build autonomous agents”, Patel said. “The unsolved problem is building accurate agents for contexts where errors have consequences. Neuro fills that gap”.
Neuron7 is building a system that knows its limits — one that reasons carefully, acts responsibly and earns trust where it matters most. In a space dominated by speculation, that discipline may well redefine what “intelligent” really means in enterprise AI.